SkinBioTherapeutics plc
("SkinBioTherapeutics" or "the Company")
Conversion Notice and Total Voting Rights
12 March 2024 - SkinBioTherapeutics
plc, (AIM: SBTX, or the "Company"), the life science business
focused on skin health, announces that it received a Conversion
Notice on 4 March 2024 from Macquarie ("Macquarie") for £80,000 of
Convertible Bonds from the £5.0 million convertible bond facility
announced on 25 January 2024. The Company has drawn a total of
£1,600,000 under the Facility.
SkinBioTherapeutics will issue
1,108,524 ordinary shares of £0.01 per share ("Ordinary Shares") at
a conversion price of 7.216800p per Ordinary Share.
Admission and Total Voting
Rights
Application has been made for
the 1,108,524 new ordinary shares, which will
rank pari passu in all respects with the
existing ordinary shares of the Company, to be admitted to AIM,
which is expected to occur on or around 8.00 a.m. on 14 March 2024
("Admission"). Upon Admission, the total number of issued shares
and the total number of voting rights in the Company will be
192,795,949.
The above figure of 192,795,949
should be used by shareholders in the Company as the denominator
for the calculations by which they will determine if they are
required to notify their interest in, or a change to their interest
in, the share capital of the Company under the Financial Conduct
Authority's Disclosure Guidance and Transparency Rules.
Conversion Update
Purusant to the two previous
conversions announced on 9 February 2024 and 28 February 2024, a
total of 1,324,484 Ordinary shares have been converted and sold by
Macquarie Bank/CLG which represents 13% of all trading volume in
the market during the month of February 2024.
Furthermore, Macquarie Bank/CLG have
agreed to no further conversions for the month of March unless
price and volumes reach certain agreed higher
thresholds.
-Ends-
The information communicated in this announcement contains
inside information for the purposes of Article 7 of the Market
Abuse Regulation (EU) No. 596/2014.
|
For
more information please contact:
|
SkinBioTherapeutics plc
Stuart J. Ashman, CEO
Manprit Randhawa, CFO
|
Tel:
+44 (0) 191 495 7325
|
|
Cavendish Capital Markets Limited
(Nominated Adviser & Broker)
Giles Balleny, Dan Hodkinson
(Corporate Finance)
Charlie Combe (Broking)
Dale Bellis, Tamar Cranford-Smith
(Sales)
|
Tel:
+44 (0) 20 7220 0500
|
|
Instinctif Partners (financial press)
Melanie Toyne-Sewell / Jack
Kincade
|
Tel:
+44 (0) 20 7457 2020
SkinBioTherapeutics@instinctif.com
|
|
Notes
to Editors
About SkinBioTherapeutics plc
SkinBioTherapeutics
is a life science company focused on skin health. The Company's
proprietary platform technology, SkinBiotix®, is based upon
discoveries made by Professor Catherine O'Neill and Professor
Andrew McBain.
The
Company is targeting a number of skin healthcare sectors, the most
advanced of which are cosmetic skincare and food supplements to
modulate the immune system by harnessing the gut-skin axis. In each
area SkinBioTherapeutics plans to exemplify its technology through
human studies. The Company's first product, AxisBiotix-Ps™, a food
supplement to address the symptoms of mild to moderate
psoriasis.
The
Company listed on AIM in April 2017 and is based in Newcastle,
UK. For more information, visit: www.skinbiotherapeutics.com
and www.axisbiotix.com.
